Show simple item record

dc.contributor.authorMagnussen, Anette L.
dc.contributor.authorMills, Ian
dc.date.accessioned2022-04-21T09:12:19Z
dc.date.available2022-04-21T09:12:19Z
dc.date.created2022-01-20T09:54:53Z
dc.date.issued2021
dc.identifier.issn0007-0920
dc.identifier.urihttps://hdl.handle.net/11250/2991879
dc.description.abstractA functional vascular system is indispensable for drug delivery and fundamental for responsiveness of the tumour microenvironment to such medication. At the same time, the progression of a tumour is defined by the interactions of the cancer cells with their surrounding environment, including neovessels, and the vascular network continues to be the major route for the dissemination of tumour cells in cancer, facilitating metastasis. So how can this apparent conflict be reconciled? Vessel normalisation—in which redundant structures are pruned and the abnormal vasculature is stabilised and remodelled—is generally considered to be beneficial in the course of anti-cancer treatments. A causality between normalised vasculature and improved response to medication and treatment is observed. For this reason, it is important to discern the consequence of vessel normalisation on the tumour microenvironment and to modulate the vasculature advantageously. This article will highlight the challenges of controlled neovascular remodelling and outline how vascular normalisation can shape disease management.en_US
dc.language.isoengen_US
dc.publisherNatureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleVascular normalisation as the stepping stone into tumour microenvironment transformationen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1038/s41416-021-01330-z
dc.identifier.cristin1985727
dc.source.journalBritish Journal of Canceren_US
dc.source.pagenumber324-336en_US
dc.identifier.citationBritish Journal of Cancer. 2021, 125 (3), 324-336.en_US
dc.source.volume125en_US
dc.source.issue3en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal